• AcuCort set out plans to use proceeds from its ongoing rights issue to fund its FDA process for Zeqmelit in the U.S.
• Work will focus on preparations for a planned New Drug Application filing, positioning the product for a future U.S. launch.
• Capital is also earmarked for continued international expansion alongside the U.S. regulatory push.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AcuCort AB published the original content used to generate this news brief via Cision (Ref. ID: 202610060300BITN____UKPR__SV_20261005-BIT-9316-0) on October 06, 2026, and is solely responsible for the information contained therein.